42 news items
Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma
REGN
16 Jun 24
, a retrospective study of patient outcomes that compared investigational linvoseltamab to real-world standard-of-care treatment in clinical practice
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
REGN
15 Jun 24
, June 15, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
REGN
13 Jun 24
(GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company
Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA)
REGN
11 Jun 24
® (aflibercept) Injection), other litigation and other proceedings and government investigations relating to the Company and/or its
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
REGN
5 Jun 24
(GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company
knn2yf9m5j94eis280hni2ks5vq 2xznnmndkdoo4u0anllt1qgrmnhn
FGEN
REGN
4 Jun 24
Tuesday morning after the company said the FDA cleared its Investigational New Drug (IND) of FG-3165. FibroGen also announced a new
7i9kln7 w1m9aeo83na09e8u7wvvgnywqz7nuof9mt
REGN
3 Jun 24
New York, New York--(Newsfile Corp. - June 3, 2024) - Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals
8szqp vrqef85xyumu59i
FGEN
REGN
3 Jun 24
in Monday’s after-hours session after the company announced the FDA cleared its Investigational New Drug (IND) for FG-3165. The company also
arnk2obgn3mfm307b75cdqa4q1n64diu9ysh2ia6n3lw6eojpv2sshjt
REGN
SNY
31 May 24
Investigational Drug Shows Potential.
Price Action: SNY shares were trading higher by 0.63% at $48.13 premarket at the last check on Friday.
Photo by HJBC via Shutterstock
60jheqk2diut6w0s
REGN
31 May 24
. The use of Dupixent in COPD is investigational and is not yet approved by global regulatory authorities. About
tgn1z77nbfns01mk705 bccms4uoejageu
REGN
31 May 24
is September 27, 2024. The use of Dupixent in COPD is investigational and is not yet approved by global regulatory authorities
w9p9ma6o8r0rdatfmq
REGN
31 May 24
play in the disease progression through the investigation of two potentially first-in-class biologics, Dupixent and itepekimab. Dupixent
bds8c1 n4rvabkjqda9iftxh6cc4u9kcsp4bke4vjp13
REGN
31 May 24
different types of inflammation play in the disease progression through the investigation of two potentially first-in-class biologics, Dupixent
96wm3ytie6btaog
REGN
30 May 24
, May 30, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron
wby u4nikxbdikr6u3g3k7iq1
BHVN
REGN
29 May 24
on investigating a new drug. Biohaven anticipates to have Myostatin program data for Phase 3 spinal muscular atrophy in the second half of 2024.
Related
659r1kogbbzk2rexcn8bos20hiu
REGN
28 May 24
(GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company
9xngeu8mpt3o lelp6hpywtbovkb48cvw5g86tgvux
ABBV
ACAD
BAYRY
24 May 24
Federal Trade Commission Investigates Drug Shortages Amid Allegations Of Market Manipulation.
Price Action
0sy102oh607yq7xbmwqirt03611xl890qt9wyg l9z9y2mfmi
REGN
23 May 24
historically proven unresponsive to immunotherapy Ongoing REGN7075 Phase 1/2 trial is investigating a potentially
3mj65kp680zj1s7iv
REGN
22 May 24
, May 22, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron
f94irjlfoap6qg4mo2wzk3 lnrsx2jttwec
REGN
20 May 24
(GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company